Kissei Pharmaceutical Co., Ltd. (KSPHF)
KSPHF Stock Price Chart
Explore Kissei Pharmaceutical Co., Ltd. interactive price chart. Choose custom timeframes to analyze KSPHF price movements and trends.
KSPHF Company Profile
Discover essential business fundamentals and corporate details for Kissei Pharmaceutical Co., Ltd. (KSPHF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
17 Mar 2017
Employees
1.78K
Website
https://www.kissei.co.jpCEO
Mutsuo Kanzawa
Description
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. Its products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was incorporated in 1946 and is headquartered in Matsumoto, Japan.
KSPHF Financial Timeline
Browse a chronological timeline of Kissei Pharmaceutical Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 2 Feb 2026
Upcoming earnings on 3 Nov 2025
Earnings released on 29 Jul 2025
EPS came in at $0.75 surpassing the estimated $0.47 by +59.46%, while revenue for the quarter reached $153.98M , beating expectations by +2.31%.
Earnings released on 7 May 2025
EPS came in at $0.50 surpassing the estimated $0.42 by +20.61%, while revenue for the quarter reached $155.82M , beating expectations by +16.05%.
Dividend declared on 7 May 2025
A dividend of $0.42 per share was announced, adjusted to $0.42.
Dividend declared on 7 May 2025
A dividend of $0.42 per share was announced, adjusted to $0.42. The dividend will be paid on 1 Dec 2025.
Earnings released on 3 Feb 2025
EPS came in at $0.53 falling short of the estimated $0.54 by -2.77%, while revenue for the quarter reached $147.57M , beating expectations by +6.51%.
Earnings released on 5 Nov 2024
EPS came in at $0.18 falling short of the estimated $0.54 by -66.50%, while revenue for the quarter reached $148.20M .
Earnings released on 30 Jul 2024
EPS came in at $0.58 surpassing the estimated $0.38 by +51.19%, while revenue for the quarter reached $131.77M , beating expectations by +7.13%.
Earnings released on 7 May 2024
EPS came in at $0.41 falling short of the estimated $0.73 by -43.83%, while revenue for the quarter reached $116.81M , missing expectations by -4.43%.
Dividend declared on 7 May 2024
A dividend of $0.37 per share was announced, adjusted to $0.37. The dividend was paid on 25 Jun 2025.
Dividend declared on 7 May 2024
A dividend of $0.31 per share was announced, adjusted to $0.31. The dividend was paid on 3 Dec 2024.
Earnings released on 30 Jan 2024
EPS came in at $0.00 falling short of the estimated $0.38 by -99.21%, while revenue for the quarter reached $1.06M , missing expectations by -99.23%.
Earnings released on 30 Sept 2023
EPS came in at $0.00 falling short of the estimated $0.34 by -99.31%, while revenue for the quarter reached $791.05K , missing expectations by -99.35%.
Earnings released on 30 Jun 2023
EPS came in at $0.00 falling short of the estimated $0.34 by -99.01%, while revenue for the quarter reached $925.83K , missing expectations by -99.25%.
Dividend declared on 8 May 2023
A dividend of $0.27 per share was announced, adjusted to $0.27. The dividend was paid on 26 Jun 2024.
Dividend declared on 8 May 2023
A dividend of $0.27 per share was announced, adjusted to $0.27. The dividend was paid on 4 Dec 2023.
Earnings released on 31 Mar 2023
EPS came in at $0.00 falling short of the estimated $1.02 by -99.53%, while revenue for the quarter reached $900.83K , missing expectations by -99.39%.
Earnings released on 31 Jan 2023
EPS came in at $72.45 surpassing the estimated $19.00 by +281.32%, while revenue for the quarter reached $1.10M , missing expectations by -99.17%.
Earnings released on 8 Nov 2022
EPS came in at $36.67 surpassing the estimated $24.00 by +52.79%, while revenue for the quarter reached $791.96K , missing expectations by -99.26%.
Earnings released on 1 Aug 2022
EPS came in at $35.47 falling short of the estimated $44.25 by -19.84%, while revenue for the quarter reached $882.29K , missing expectations by -99.26%.
Earnings released on 10 May 2022
EPS came in at $132.32 surpassing the estimated -$0.26 by +50.43K%, while revenue for the quarter reached $1.03M , missing expectations by -99.17%.
Dividend declared on 10 May 2022
A dividend of $0.30 per share was announced, adjusted to $0.30. The dividend was paid on 23 Jun 2023.
Dividend declared on 10 May 2022
A dividend of $0.28 per share was announced, adjusted to $0.28. The dividend was paid on 2 Dec 2022.
Earnings released on 1 Feb 2022
EPS came in at $25.00 surpassing the estimated $4.00 by +525.00%, while revenue for the quarter reached $1.34M , missing expectations by -99.13%.
Earnings released on 9 Nov 2021
EPS came in at $43.85 surpassing the estimated $32.00 by +37.03%, while revenue for the quarter reached $1.27M .
Earnings released on 2 Aug 2021
EPS came in at $79.02 surpassing the estimated $2.00 by +3.85K%, while revenue for the quarter reached $1.35M .
Earnings released on 11 May 2021
EPS came in at -$24.83 , while revenue for the quarter reached $152.45M .
Dividend declared on 11 May 2021
A dividend of $0.23 per share was announced, adjusted to $0.23. The dividend was paid on 24 Jun 2022.
Dividend declared on 11 May 2021
A dividend of $0.25 per share was announced, adjusted to $0.25. The dividend was paid on 2 Dec 2021.
Earnings released on 1 Feb 2021
EPS came in at $43.75 , while revenue for the quarter reached $192.68M .
Earnings released on 5 Nov 2020
EPS came in at $57.18 surpassing the estimated $15.00 by +281.20%, while revenue for the quarter reached $153.67M .
Dividend declared on 12 May 2020
A dividend of $0.25 per share was announced, adjusted to $0.24. The dividend was paid on 25 Jun 2021.
Dividend declared on 12 May 2020
A dividend of $0.26 per share was announced, adjusted to $0.26. The dividend was paid on 3 Dec 2020.
KSPHF Stock Performance
Access detailed KSPHF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.